Gender differences in hidradenitis suppurativa characteristics: A retrospective cohort analysis

Shih, Terri; Seivright, Justine; McKenzie, Shanice A; Harview, Christina L.; Truong, Amy; Shi, Vivian Y.; Bennett, Richard G.; Hsiao, Jennifer L.

doi:10.1016/j.ijwd.2021.07.003

Cited by 7 publications

(5 citation statements)

References 5 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Te analysis of the demographic data showed higher percentage of male patients in our cohort (55%) similarly to other study confrming the fact, that men have increased disease severity [18].…”

Section: Discussionsupporting

confidence: 90%

Employing Adalimumab in Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Real-Life Multicenter Data from the Czech Republic

Smetanova

Marques

Kojanová

et al. 2023

Dermatologic Therapy

View full text Add to dashboard Cite

Adalimumab is the only approved biologic treatment for moderate-to-severe hidradenitis suppurativa, nonetheless, long-term data from real-life setting are still limited. The objective of this observational multicenter study was to evaluate the effectiveness, safety, and drug survival of adalimumab in patients with hidradenitis suppurativa included in the BIOREP registry. A total of 299 patients who initiated adalimumab therapy for hidradenitis suppurativa from 2011 to November 2021 were included. The Dermatology-Life-Quality-Index (DLQI), pain scale, the number of abscesses, inflammatory nodules and draining tunnels, and International Hidradenitis Suppurativa Severity Score System (IHS4) were recorded in the 0th, 3rd, and 6th months; then every 6 months during the ongoing adalimumab treatment. Studied patients underwent treatment for up to 48 months, with the average duration of treatment lasting 2.3 years. The mean age of the patients was 44.9 years, 79% were smokers or ex-smokers, 54.8% were obese, and 26.4% were overweight, the mean BMI was 30.8. The mean time from diagnosis to initiation adalimumab therapy was 9.1 years. The number of patients with severe IHS4 dropped from the initial 249 (83.3%) to 65 (30.1%) after 12 months and this trend was maintained up to the 48th month. A decreasing number of inflammatory lesions were rapid and sustained and correlated to the improvement of patients’ quality of life, the mean DLQI score dropped from 17.6 to 8.5 after 3 months and to 5, 7 after 48 months. No unexpected risk signals were observed. Our long-term study demonstrates the effectiveness and safety of adalimumab in a real-life setting.

show abstract

Section: Discussionsupporting

confidence: 90%

Employing Adalimumab in Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Real-Life Multicenter Data from the Czech Republic

Smetanova

Marques

Kojanová

et al. 2023

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…The reasons for this finding are likely multifaceted, include previously reported factors such as limited disease awareness, stigma associated with intertriginous lesions, and gender differences in healthcare utilization. 3,4 Although not significant, the White race was associated with diagnostic delay. Because HS is more prevalent in African-American populations, providers may have decreased suspicion of this condition in White populations.…”

mentioning

confidence: 69%

Section: Dear Editorsmentioning

confidence: 99%

Female sex and younger age are associated with hidradenitis suppurativa diagnostic delay

Rinderknecht,

Naik

2023

International Journal of Women’s Dermatology

View full text Add to dashboard Cite

“…Indeed, female sex has been positively associated with breast and/or inguinal lesions (the front part of the body), whereas male sex was associated with greater gluteal, perianal and/or nape involvement (the back of the body) [ 13 , 14 , 15 , 16 , 17 ]. In addition, HS severity was positively associated with male sex according to Hurley stage [ 15 , 17 ], Sartorius score [ 16 ] and the International Hidradenitis Suppurativa Severity Score System (IHS4) [ 18 ]. Few studies have investigated gender differences in age of HS onset.…”

Section: Hs and Gendermentioning

confidence: 99%

“…Few studies have investigated gender differences in age of HS onset. According to some researchers, female HS patients had earlier disease onset than male patients [ 15 , 17 , 19 , 20 ]. Conversely, Morss and colleagues found no differences between males and females in terms of disease onset [ 21 ].…”

Section: Hs and Gendermentioning

confidence: 99%

Hidradenitis Suppurativa: The Influence of Gender, the Importance of Trigger Factors and the Implications for Patient Habits

et al. 2022

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a debilitating, chronic, inflammatory skin disease primarily affecting apocrine gland-rich areas of the body. On the one hand, the presence of triggering factors—some identified, others only hypothesized—may initiate or perpetuate the pathogenic process of HS. In addition to cigarette smoking and diet, other trigger factors, including choice of clothing, are frequently observed in clinical practice. On the other hand, the presence of disease may influence habits of HS patients. Indeed, high incidences of sexual and sleep impairment have been reported in these patients. Consequently, alcohol and substance abuse may be a coping strategy for the emotional and psychological disease burden. Furthermore, a greater awareness of gender differences in HS may be important for dermatologists in their own clinical practice (i.e., pregnancy and breastfeeding). Consequently, in this loop interaction, comprehensive knowledge of all factors involved is crucial for the management of HS patients. Thus, the objective of this review is to (i) discuss the influence of gender on HS, (ii) summarize the most frequent triggering factors of HS and (iii) analyze the impact of HS on patient habits.

show abstract

Gender differences in hidradenitis suppurativa characteristics: A retrospective cohort analysis

Cited by 7 publications

References 5 publications

Employing Adalimumab in Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Real-Life Multicenter Data from the Czech Republic

Employing Adalimumab in Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Real-Life Multicenter Data from the Czech Republic

Female sex and younger age are associated with hidradenitis suppurativa diagnostic delay

Hidradenitis Suppurativa: The Influence of Gender, the Importance of Trigger Factors and the Implications for Patient Habits

Contact Info

Product

Resources

About